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Introduction: A study was conducted to determine whether the human leukocyte antigen (HLA) B alleles are
implicated in the susceptibility to Henoch-Schönlein purpura (HSP) in the largest series of Caucasian HSP patients
ever assessed for genetic studies.
Methods: The study population was composed of 349 Spanish patients diagnosed with HSP fulfilling the American
College of Rheumatology and the Michel et al. classification criteria, and 335 sex and ethnically matched controls. HLA-B
phenotypes were determined by sequencing-based typing (SBT) and analyzed by chi-square or Fisher exact test.
Results: A statistically significant increase of HLA-B*41:02 allele in HSP patients when compared with controls was
found (8.3% versus 1.5% respectively; P = 0.0001; OR (odds ratio) =5.76 [2.15-19.3]). These results remained statistically
significant after adjusting for Bonferroni correction (P = 0.0028). An internal validation also confirmed the susceptibility
effect on HSP associated with HLA-B*41:02 (OR = 5.70 [1.98-16.44]). Since a former study described an association
between HLA-DRB1*01:03 and HSP susceptibility, we also evaluated the implication of HLA-B*41:02 independently of
HLA-DRB1*01:03. Interestingly, the association remained statistically significant (P = 0.0004, OR = 4.97 [1.8-16.9]). No
HLA-B association with specific HSP clinical features was found.
Conclusions: Our study indicates that HLA-B*41:02 is associated with the susceptibility to HSP in Spanish patients
irrespective of HLA-DRB1 status.Introduction
Henoch-Schönlein purpura (HSP), also called immuno-
globulin-A (IgA) vasculitis, is a leukocytoclastic vasculitis
characterized by IgA dominant immune deposits involving
mainly the skin but other tissues as well. HSP is more com-
mon in children but it is not exceptional in adults [1]. The
main feature of this vasculitis is a palpable purpura* Correspondence: miguelaggay@hotmail.com
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stated.involving predominantly the lower extremities. Besides
skin involvement, HSP often causes joint pain and
gastrointestinal complications [2]. Renal manifestations
may also be observed in HSP patients, mainly in adults,
indicating a poor prognosis of this disorder [2].
HSP has a multifactorial pathology in which a wide variety
of pathogens, drugs, and other environmental exposures
have been involved [3]. Furthermore, several studies have re-
vealed the relevant role of some genetic variants (including
those located in the human leukocyte antigen (HLA) system
[4]) in both susceptibility and HSP clinical heterogeneity.
The HLA region includes a group of genes located in
chromosome 6 (6p21) that encodes for proteins on theentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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immune system in humans [5]. HLA has been described
as a common genetic component that underlies immune-
mediated diseases [6], being associated with more diseases
than any other region of the human genome [5]. In this
regard, the association between class II HLA genes and
HSP susceptibility in Caucasians has been well-established
in a recent well-powered study [4]. In this work, the sus-
ceptibility effect of HLA-DRB1*01 (mainly due to HLA-
DRB1*01:03 allele) was confirmed, whereas a potential
protective effect of HLA-DRB1*03 (mainly due to HLA-
DRB1*03:01 allele) was also postulated [4]. However, the
influence of class I HLA genes in HSP Caucasian patients
still remains unclear since only a few studies, performed
in small cohorts of HSP patients, have addressed this issue
[7-10]. Although no association between class I HLA
(HLA-A, HLA-B, and HLA-C) genes and HSP was found
by Ostergaard et al. [10], HLA-B*35 allele has been sug-
gested to be a potential marker of renal complications sec-
ondary to HSP by Nathwani et al., Nyulassy et al. and
Amoli et al. [7-9].
Taken together these considerations prompted us to inves-
tigate the potential implication of HLA-B gene in the suscep-
tibility to HSP. For this purpose we took advantage of the
largest series of Caucasian patients with this vasculitis ever
assessed for genetic studies.
Methods
Patients and study protocol
A series of 349 Spanish patients with cutaneous vasculitis
who fulfilled Michel et al. [11]. classification criteria for HSPTable 1 Main clinical features of a series of 349 Spanish patie
Main characteristics
Children (age ≤20 years)/adults (age >20 years)
Male/female
Age at the onset of the disease (years)
mean ± SD
median (IQR)
Duration of follow-up (years, mean ± SD)
Palpable purpura and/or maculopapular rash
Arthralgia and/or arthritis
Gastrointestinal manifestations (if ‘a’ and/or ‘b’)
a) Bowel angina
b) Gastrointestinal bleeding
Renal manifestations (if any of the following characteristics)
a) Hematuria
b) Proteinuria
c) Nephrotic syndrome
d) Renal sequelae (persistent renal involvement)a
aAt last follow-up. HSP: Henoch-Schönlein purpura; SD: standard deviation; IQR: intewere included in the present study. According to these cri-
teria, they were classified as having HSP if they fulfilled three
or more of the following characteristics: palpable purpura,
bowel angina, gastrointestinal bleeding, macroscopic or
microscopic hematuria, age at disease onset ≤20 years, and
no previous history of medications prior to the onset of the
disease. Also, all patients included in this series were re-
quired to fulfill the American College of Rheumatology
classification criteria for HSP [12]. Blood samples were
obtained from patients recruited from Hospital Universi-
tario Lucus Augusti (Lugo), Hospital Universitario
Marqués de Valdecilla (Santander), Hospital Universitario
La Princesa (Madrid), Hospital Universitario San Cecilio
(Granada), Hospital Universitario Virgen del Rocío
(Sevilla) and Hospital Universitario de Basurto (Bilbao).
Information on the main clinical features of the whole
series of 349 HSP Spanish patients recruited in this study
is shown in Table 1. Hematuria with or without protein-
uria and severe gastrointestinal manifestations were fre-
quently observed in these patients. However, only 24 of
the 349 patients (6.8%) had persistent renal involvement
(renal sequelae) at last follow-up.
A set of 335 sex and ethnically matched controls without
history of cutaneous vasculitis or any other autoimmune dis-
ease comprising blood donors from the National DNA Bank
Repository (Salamanca, Spain), was also included in the
study.
A subject’s written consent was obtained according to
the declaration of Helsinki, and the study was approved
by the Ethics Committees of Galicia for Hospital
Universitario Lucus Augusti, of Cantabria for Hospitalnts with HSP
% (n/N)
283/66
176/173
14.8 ± 18.0
7 (5 to 18)
3.3 ± 4.3
100 (349/349)
56.4 (197/349)
53.6 (187/349)
52.1 (182/349)
16.0 (56/349)
35.5 (124/349)
34.6 (121/349)
32.9 (115/349)
4.3 (15/349)
6.8 (24/349)
rquartile range.
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Hospital Universitario La Princesa, of Andalucía for
Hospital Universitario San Cecilio and Hospital Univer-
sitario Virgen del Rocío, and of País Vasco for Hospital
Universitario de Basurto.
Genotyping
High-molecular-weight genomic DNA was extracted
from whole blood using the QIAamp DNA Blood Mini
Kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s instructions.
All DNA samples were stored at −20°C until the HLA
analysis. Class I HLA B locus high-resolution typing was
performed through sequencing-based typing (SBT), by
using the SBTexcellerator Kit and analyzed with the
SBTengine®-SBT HLA typing software (GenDx, Utrecht,
The Netherlands) following the manufacturer’s instructions.
Positive controls were used to ensure the quality control
for the genotyping procedures. These samples, of known
sequence, were obtained from External Proficiency Testing
Programs (GECLID – Spanish Society of Immunology),
following the European Federation of Immunogenetics stan-
dards. Additionally, negative controls were included to dis-
card the effect of DNA contamination.
Statistical analysis
Continuous data are described as mean and standard devi-
ation (mean ± SD) and categorical variables as percentages.
The strength of association between HSP and HLA-B
phenotypes was estimated using odds ratios (OR) and
95% confidence intervals (CI). Levels of significance
were determined using contingency tables by either the
chi-square test or Fisher exact (expected values below 5)
analysis. Results were adjusted for Bonferroni correction.
To obtain an internal validation, we carried out a boot-
strap test with 1,000 replications.
All analyses were performed with STATA statistical
software 12/SE (Stata Corp., College Station, TX, USA).
The linkage disequilibrium between HLA alleles was
calculated using the PLINK software [13].
Results
When HSP patients were compared with matched controls,
some differences in HLA-B phenotype frequencies were ob-
served (Table 2). In this regard, the HLA-B*41 phenotype
was significantly increased in HSP patients compared to
controls (10.1% versus 3.3%, respectively; P = 0.0007; OR =
3.18 (1.53 to 7.07)). This association was mainly due to the
HLA-B*41:02 allele (8.3% in HSP patients versus 1.5% in
controls; P = 0.0001; OR = 5.76 (2.15 to 19.3)) and remained
statistically significant after adjusting for Bonferroni correc-
tion (P = 0.0028) (Table 2). Since the potential effect of
HLA-B*41:02 on HSP had not previously been reported, we
carried out a bootstrapping procedure that confirmed thesusceptibility effect on HSP associated with HLA-B*41:02
(OR = 5.70 (1.98 to 16.44)). However, no statistically signifi-
cant results were observed regarding other HLA-B pheno-
types and HSP susceptibility (Table 2).
Since in a recent study we disclosed an association be-
tween HLA-DRB1*01:03 and HSP susceptibility [4], we also
evaluated whether the implication of HLA-B*41:02 was
independent of the HLA-DRB1*01:03 status (Table 3).
Interestingly, and as shown in Table 3, the associa-
tion of HLA-B*41:02 with HSP susceptibility remained
statistically significant irrespective of HLA-DRB1*01:03
(P = 0.0004, OR = 4.97 (1.8 to 16.9)) (Table 3). To further
confirm the independence of both alleles, we calculated
the linkage disequilibrium between them in our study
population. As expected, the r2 value showed that both
alleles were independent (r2 = 0.003).
In a further step we assessed whether HLA-B pheno-
type differences might exist according to specific fea-
tures of the disease, such as age at disease onset before
and after 20 years, presence of joint, gastrointestinal or
renal manifestations. In this regard, we did not observe
any trend toward significance between different HLA-B
phenotypes and gastrointestinal manifestations. Regard-
ing age at disease diagnosis, we only found a statistically
marginal increase in the frequency of adults (>20 years
old) carrying the HLA-B*45:01 allele. However, this mar-
ginal significance was lost after Bonferroni correction. A
statistically significant increase in HLA-B*14:02 and
53:01 was detected in HSP patients with renal manifesta-
tions (P = 0.0113 and 0.0415, respectively). However,
similarly to the previous case, when we corrected these
results by Bonferroni, this significance was lost.
Finally, 12 HSP patients with renal manifestations car-
ried the HLA-B*41:02 allele. However, no statistically
significant association was observed between the pres-
ence of this HLA-B allele and the presence of renal man-
ifestations (P = 0.513; OR = 1.31 (0.53 to 3.17)).
Discussion
The vasculitides constitute a heterogeneous group of
diseases that have in common the presence of inflamma-
tion of the blood vessels [1,14]. Their complex etiology
is far from being completely elucidated. Both environ-
mental and genetic factors appear to influence the devel-
opment and progression of these conditions, HLA being
the main genetic factor related to these diseases. Al-
though the effect of the class II HLA genes in the sus-
ceptibility of HSP in Caucasians has recently been
characterized [4], there is scarce information on the po-
tential implication of class I HLA genes in HSP [7-10].
Because of that, we have performed a study to provide
evidence of the potential implications of the HLA-B gene
in the susceptibility to HSP. For this purpose, we re-
cruited the largest series of Caucasian patients with this
Table 2 HLA-B phenotype frequencies in patients with HSP and controls
HLA-B Patients with HSP (number = 349) Controls (number = 335) P OR (95% CI)
B*07 B*07:02 52 (14.9) 49 (14.6) 0.92 1.02 (0.65 to 1.60)
B*08 B*08:01 29 (8.3) 31 (9.2) 0.66 0.88 (0.50 to 1.56)
B*13 B*13:02 7 (2.0) 8 (2.4) 0.73 0.84 (0.25 to 2.67)
B*14 B*14:01 8 (2.3) 5 (1.5) 0.44 1.54 (0.44 to 6.07)
B*14:02 29 (8.3) 47 (14.0) 0.017 0.55 (0.33 to 0.93)
B*15 B*15:01 25 (7.2) 22 (6.6) 0.76 1.10 (0.58 to 2.10)
B*15:17 4 (1.2) 5 (1.5) 0.69 0.76 (0.15 to 3.60)
B*18 B*18:01 36 (10.3) 41 (12.2) 0.42 0.82 (0.49 to 1.36)
B*27 B*27:05 20 (5.9) 20 (6.0) 0.89 0.96 (0.48 to 1.91)
B*35 B*35:01 50 (14.3) 51 (15.2) 0.74 0.93 (0.59 to 1.45)
B*35:03 20 (5.7) 8 (2.4) 0.027 2.48 (1.02 to 6.61)
B*38 B*38:01 10 (3.0) 27 (8.1) 0.0027 0.34 (0.14 to 0.73)
B*39 B*39:01 8 (2.4) 7 (2.1) 0.85 1.10 (0.34 to 3.61)
B*40 B*40:01 16 (4.6) 17 (5.1) 0.76 0.89 (0.42 to 1.93)
B*40:02 10 (3.0) 5 (1.5) 0.22 1.94 (0.59 to 7.33)
B*41a B*41:01 6 (1.8) 6 (1.8) 0.94 0.95 (0.25 to 3.62)
B*41:02 28 (8.3) 5 (1.5) 0.0001 5.76 (2.15 to 19.3)
B*44 B*44:02 35 (10.0) 16 (4.8) 0.009 2.22 (1.17 to 4.39)
B*44:03 61 (17.5) 71 (21.2) 0.22 0.79 (0.53 to 1.17)
B*45 B*45:01 7 (2.0) 11 (3.3) 0.29 0.60 (0.19 to 1.73)
B*49 B*49:01 24 (7.2) 34 (10.1) 0.12 0.65 (0.36 to 1.16)
B*50 B*50:01 26 (7.7) 16 (4.8) 0.14 1.60 (0.81 to 3.26)
B*51 B*51:01 53 (15.2) 56 (16.7) 0.59 0.89 (0.58 to 1.37)
B*52 B*52:01 5 (1.5) 11 (3.3) 0.11 0.43 (0.11 to 1.35)
B*53 B*53:01 12 (3.6) 13 (3.9) 0.76 0.88 (0.36 to 2.13)
B*55 B*55:01 4 (1.2) 12 (3.6) 0.035 0.31 (0.07 to 1.04)
B*57 B*57:01 22 (6.3) 12 (3.6) 0.10 1.81 (0.84 to 4.10)
B*58 B*58:01 13 (3.7) 11 (3.3) 0.75 1.14 (0.46 to 2.85)
a10.1% in HSP patients versus 3.3% in controls; P = 0.0007; OR = 3.18 (1.53 to 7.07); values are expressed as number (n) and percentages (%); the result that remained
statistically significant after adjusting for Bonferroni correction (pBNF = 0.0028) is highlighted in bold. HLA: human leukocyte antigen; HSP: Henoch- Schönlein purpura;
OR: odds ratio; CI: confidence interval.
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our findings support the role of the HLA-B*41:02 as a
susceptibility marker of this disease irrespective of
HLA-DRB1 status. However, in contrast to previous
studies [7-9], we could not confirm an association be-
tween HLA-B alleles and renal manifestations or any
other specific features of this vasculitis. In this regard,Table 3 HLA-B*41:02 and HLA-DRB1*01:03 are independently
HLA-DRB1*01:03 HLA-B*41:02 Patients with HSP
- - 270
- + 23
+ - 48
+ + 1
HLA: human leukocyte antigen; HSP: Henoch- Schönlein purpura; OR: odds ratio; CIconsidering that our analysis was performed in a well-
powered cohort of HSP patients, we cannot exclude the
possibility that previous results might have been the
result of a type I error. Because of that, additional stud-
ies including large series of patients are needed to fully
establish the association of the HLA-B locus with spe-
cific features of HSP.associated with increased susceptibility to HSP
Controls P OR (95% CI)
292 - Ref.
5 0.0004 4.97 (1.8 to 16.9)
6 <0.001 8.65 (3.6 to 25.1)
0 0.2988 -
: confidence interval.
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ated with different types of primary systemic vasculitis
in Caucasians. An association of HLA-B*15, HLA-B*8,
HLA-Cw3 and HLA-Cw6 with giant cell arteritis
(a large-sized blood vessel vasculitis) has been reported
[15-17]. Although the involvement of class I HLA genes
in Kawasaki disease (a vasculitis involving medium-
sized blood vessels) is controversial, HLA-B*51 and
HLA-B*44 have been proposed to be associated with
this disease [18,19]. Additionally, HLA-B*50 has been
shown to be related to susceptibility to granulomatosis
with polyangiitis, a small-sized vessel anti-neutrophil
cytoplasmic antibody-associated vasculitis [20]. Finally,
a recently published analysis of imputed genome wide
association study data described an association between
a genetic variant located between the HLA-B and MICA
loci and Behçet’s disease [21]. Regarding HLA-B*35:03,
other authors reported an increase of this allele in over-
all HSP [22]. Even if in our study we observed a signifi-
cantly increased frequency of this allele in our HSP
cohort, this significance was lost after Bonferroni cor-
rection. However, this lack of significance after correc-
tion in our study might be due to sample size or also to
differences between our cohort and that studied by Peru
et al. [22].
Conclusions
The analysis of our data supports an association of HLA-
B*41:02 with susceptibility to HSP in Caucasians, irrespect-
ive of HLA-DRB1 status. These results may have potential
clinical implications as they may help to better identify indi-
viduals at risk for this vasculitis.
Abbreviations
CI: confidence interval; HLA: Human Leukocyte Antigen; HSP:
Henoch-Schönlein purpura; IgA: immunoglobulin-A; IQR: interquartile range;
OR: odds ratio; SBT: sequencing-based typing; SD: standard deviation.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RLM, FG and BSP participated in the design of the study, data analysis and
helped to draft the manuscript. SC, NOC and JM have been involved in the
acquisition and interpretation of data and in revising it critically for
important intellectual content. JL carried out the analysis and interpretation
of the data, and helped to draft and revise the final manuscript. BU, SR-M,
VM, TP, VC-R, AM, JAMF, ANP, DA, MA, ER, MLL, JMB-M and EG-A participated
in the acquisition and interpretation of data and helped to draft the
manuscript. MC-J, LO-F, FGE and JGO-V carried out genotyping and helped
to draft the manuscript. RB and MAG-G made substantial contributions to
conception and design of the study, acquisition of data, coordination and
helped to draft the manuscript and have given final approval of the version
to be published. All authors agree to be accountable for all aspects of the
work in ensuring that questions related to the accuracy or integrity of any
part of the work are appropriately investigated and resolved. All authors have
read and approved the final manuscript.
Authors’ information
Drs Gonzalez-Gay and Blanco shared senior authorship in this study.Acknowledgements
We wish to thank all the patients with HSP and controls who participated to
make this study possible. We want to specially thank Patricia Fuentevilla
Rodríguez, María Del Camino Villa Llamazares and María Eugenia Cuadrado
Mantecón for their technical assistance. This study was supported by a grant
from ‘Fondo de Investigaciones Sanitarias’ PI12/00193 (Spain). RLM is a
recipient of a Sara Borrell postdoctoral fellowship from the Instituto de Salud
Carlos III at the Spanish Ministry of Health (Spain) (CD12/00425). FG and BU
are supported by funds from the RETICS Program (RIER) (RD12/0009/0013).
Author details
1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic
Inflammatory Diseases, Rheumatology Division, Hospital Universitario
Marqués de Valdecilla, IDIVAL, Santander, Spain. 2Medicine Department,
Hospital Universitario San Cecilio, Granada, Spain. 3Rheumatology
Department, Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain.
4Epidemiology and Computational Biology Department, School of Medicine,
University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP),
IDIVAL, Santander, Spain. 5Institute of Parasitology and Biomedicine
López-Neyra (IPBLN-CSIC) and Systemic Autoimmune Diseases Unit, Hospital
Clínico San Cecilio, Granada, Spain. 6Division of Rheumatology, Hospital
Universitario Lucus Augusti, Lugo, Spain. 7Nephrology Department, Hospital
Universitario San Cecilio, Granada, Spain. 8Immunology Department, Hospital
Universitario Virgen del Rocío, Sevilla, Spain. 9Dermatology Department, IIS-IP,
Hospital de la Princesa, Madrid, Spain. 10Rheumatology Department, Hospital
Universitario Virgen del Rocío, Sevilla, Spain. 11Rheumatology Department,
Hospital Universitario de Basurto, Bilbao, Spain. 12Immunology Department,
Hospital Universitario Marqués de Valdecilla, Santander, Spain. 13Institute of
Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain.
Received: 15 January 2015 Accepted: 8 April 2015References
1. González-Gay MA, García-Porrúa C. Epidemiology of the vasculitides.
Rheum Dis Clin North Am. 2001;27:729–49.
2. García-Porrúa C, Calviño MC, Llorca J, Couselo JM, González-Gay MA.
Henoch-Schönlein purpura in children and adults: clinical differences in a
defined population. Semin Arthritis Rheum. 2002;32:149–56.
3. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368:2402–14.
4. López-Mejías R, Genre F, Pérez BS, Castañeda S, Ortego-Centeno N, Llorca J,
et al. HLA-DRB1 association with Henoch-Schonlein purpura.
Arthritis Rheumatol. 2015;67:823–7.
5. Complete sequence and gene map of a human major histocompatibility
complex. The MHC sequencing consortium. Nature. 1999;401:921–3.
6. Klein J, Sato A. The HLA system, second of two parts. N Engl J Med.
2000;343:782–6.
7. Amoli MM, Thomson W, Hajeer AH, Calviño MC, Garcia-Porrua C, Ollier WE,
et al. HLA-B35 association with nephritis in Henoch-Schonlein purpura.
J Rheumatol. 2002;29:948–9.
8. Nathwani D, Laing RB, Smith CC, Edward N. Recurrent post-infective
Henoch-Schonlein syndrome: a genetic influence related to HLA B35?
J Infect. 1992;25:205–10.
9. Nyulassy S, Buc M, Sasinka M, Pavlovic M, Slugen I, Hirschová V, et al. The
HLA system in glomerulonephritis. Clin Immunol Immunopathol.
1977;7:319–23.
10. Ostergaard JR, Storm K, Lamm LU. Lack of association between HLA and
Schoenlein-Henoch Purpura. Tissue Antigens. 1990;35:234–5.
11. Michel BA, Hunder GG, Bloch DA, Calabrese LH. Hypersensitivity vasculitis
and Henoch-Schonlein purpura: a comparison between the 2 disorders.
J Rheumatol. 1992;19:721–8.
12. Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al.
The American College of Rheumatology 1990 criteria for the classification of
Henoch-Schonlein purpura. Arthritis Rheum. 1990;33:1114–21.
13. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al.
PLINK: a tool set for whole-genome association and population-based
linkage analyses. Am J Hum Genet. 2007;81:559–75.
14. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised
International Chapel Hill Consensus Conference Nomenclature of
Vasculitides. Arthritis Rheum. 2013;65:1–11.
López-Mejías et al. Arthritis Research & Therapy  (2015) 17:102 Page 6 of 615. Armstrong RD, Behn A, Myles A, Panayi GS, Welsh KI. Histocompatibility
antigens in polymyalgia rheumatica and giant cell arteritis. J Rheumatol.
1983;10:659–61.
16. Gonzalez-Gay MA, Rueda B, Vilchez JR, Lopez-Nevot MA, Robledo G, Ruiz
MP, et al. Contribution of MHC class I region to genetic susceptibility for
giant cell arteritis. Rheumatology (Oxford). 2007;46:431–4.
17. Kemp A, Marner K, Nissen SH, Heyn J, Kissmeyer-Nielsen F. HLA antigens in
cases of giant cell arteritis. Acta Ophthalmol (Copenh). 1980;58:1000–4.
18. Kaslow RA, Bailowitz A, Lin FY, Koslowe P, Simonis T, Israel E. Association of
epidemic Kawasaki syndrome with the HLA-A2, B44, Cw5 antigen
combination. Arthritis Rheum. 1985;28:938–40.
19. Krensky AM, Berenberg W, Shanley K, Yunis EJ. HLA antigens in
mucocutaneous lymph node syndrome in New England. Pediatrics.
1981;67:741–3.
20. Cotch MF, Fauci AS, Hoffman GS. HLA typing in patients with Wegener
granulomatosis. Ann Intern Med. 1995;122:635.
21. Hughes T, Coit P, Adler A, Yilmaz V, Aksu K, Düzgün N, et al. Identification of
multiple independent susceptibility loci in the HLA region in Behcet’s
disease. Nat Genet. 2013;45:319–24.
22. Peru H, Soylemezoglu O, Gonen S, Cetinyurek A, Bakkaloğlu SA, Buyan N,
et al. HLA class 1 associations in Henoch Schonlein purpura: increased and
decreased frequencies. Clin Rheumatol. 2008;27:5–10.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
